Before we head off to SHM CONVERGE this weekend, here are a few articles that may be of use in your practice. A random assortment from end-of-life care to ketamine in pain control, hopefully its something for everyone.

| 00.05 - Intro |

| 00.48 - CONVERGE - come visit me on Saturday in Hall F! Or email boostershots@ucsd.edu if you want to discuss at other times! |

| 01.42 - Empagliflozin delays CKD progression in diabetic or glomerular disease, but not necessarily hypertensive or renovascular disease [ACP Journal Club 2024 (subscription required), Lancet D&E 2024]

| 03.14 - Antibiotics and end of life care - I recommend you look at the paper [CID 2024] |

| 06.33 - Low dose ketamine for pain control vs. morphine → Shorter onset, but shorter duration [AJEMEN 2024]

| 08.00 - Using Deep Learning models to estimate CV risk using CXR only [AIM 2024]

references for the groups' other studies using Deep Learning: Long-term mortality from CXR [JAMA 2019], Identifying high risk smokers for lung cancer CT screening [AIM 2020]\

| 09.53 - 43s Summary (yes I lied, it wasn't 30s), disclaimers, credits, etc. |

[The appearance of external hyperlinks does not constitute endorsements by UCSF of the linked websites, or the information, products, or services contained therein. UCSF does not exercise any editorial control over the information found therein, nor does UCSF make any representation of their accuracy or completeness. All information contained in this episode are the opinions of the respective speakers and not necessarily the views their respective institutions or UCSF, and is only provided for information purposes, not to diagnose or treat.]

022 - CONVERGE, EMPA-CKD, abx @ EOL, and ketamine in the ED